MedPath

Effect of vitamin D supplements in schizophrenia

Phase 3
Recruiting
Conditions
SCHIZOPHRENIA.
Schizophrenia
Registration Number
IRCT20190313043039N1
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
46
Inclusion Criteria

People with schizophrenia admitted to Razi Hospital
The age range of 18-65 years old in men and the age range of 18-50 years in women
Diagnosis of schizophrenia based on the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) and Psychiatrist's Confirmation
PANSS score above 70
Did not receive any dietary supplements ( oral or injectable) in the past year(such as vitamin D3 and calcium)
Serum levels of the vitamin D3 below 20 ng / ml
The desire to participate in the study

Exclusion Criteria

Pregnancy or breastfeeding
comorbididty with other major psychological or neurological diseases such as bipolar disorder and multiple sclerosis
Smoking and alcohol consumption
History of compliance with certain diets
Use of serum vitamin D suppressants (such as anticonvulsants and glucocorticoids)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Components of metabolic syndrome including waist circumference, fasting blood glucose, HDL, triglyceride and blood pressure. Timepoint: Before the intervention and 8 weeks later. Method of measurement: Accordingly, the bandwidth (waist circumference), kit and autoanalyser (sugar, HDL and triglyceride) and mercury pressure gauge (blood pressure).
Secondary Outcome Measures
NameTimeMethod
Serum levels of glycogen synthase kinase 3, beta-catenin, BDNF, S100B and ZAG. Timepoint: Before the intervention and 8 weeks later. Method of measurement: ELISA.
© Copyright 2025. All Rights Reserved by MedPath